Title
Efficacy of Beraprost in Lowering Pulmonary Arterial Pressure in Children
Efficacy of Beraprost in Lowering Pulmonary Arterial Pressure in Pulmonary Arterial Hypertension Children Associated With Left to Right Shunt Congenital Heart Defect
Phase
Phase 4Lead Sponsor
Dr. Soetomo General HospitalStudy Type
InterventionalStatus
Completed No Results PostedIndication/Condition
Pediatric Pulmonary HypertensionIntervention/Treatment
Sildenafil Citrate Beraprost SodiumStudy Participants
40To analyze the efficacy of beraprost and sildenafil for treatment of pulmonary hypertension in children with left to right shunt.
analyze the efficacy and side effects.
Eligibility criteria:
Inclusion:
children aged 1-17 years with left to right shunt, diagnosed as pulmonary hypertension.
free from chronic pulmonary disease
never performed any cardiac surgical
never got any treatment for PH
agree to enroll in this study. Exclusion
1. suffer from portal hypertension, HIV and connective tissue disease 2. under interferon therapy.
Outcome measure:
Pulmonary artery pressure
0.4 mg/kgbw each time, 4 times in a day orally for 12 weeks
1 mcg /kgbw daily, divided in three dosages orally for 12 weeks
Beraprost 1mcg/kg/day, divided in 3 doses orally patient was followed up for 12 weeks, then echocardiography evaluation was performed in patient completed the study. 22 patients
Sildenafil 0.4 mg/kg/time, 4 times daily per oral patient was followed up for 12 weeks, then echocardiography evaluation was performed in patient completed the study. 20 patients
Inclusion Criteria: diagnosed as pulmonary hypertension with left to right shunt CHD (VSD, ASD, PDA and combination) agree to enroll in this study Exclusion Criteria: suffer from chronic lung disease suffer from soft tissue tumor, HIV/AIDS under interferon therapy already performed any cardiac surgery already got anti-PH remedy